Children's Health, Research & Technology
MSU-Spectrum Health Researchers Identify New Genetic Disorder
GRAND RAPIDS, Mich., Sept. 21, 2018 – Researchers from Michigan State University College of Human Medicine and physicians from Spectrum Health have identified for the first time in a human patient a genetic disorder only previously described in animal models.
The disorder is caused by mutations in a gene known as ornithine decarboxylase 1 (ODC1) and is defined by a number of clinical features including large birth weight, enlarged head size, hair loss, reduced muscle strength, skin lesions, hearing loss and developmental delays. The disorder is, as of yet, unnamed, and its long-term effects, which include impacts on the neurological system, are not completely known.
Their study is published in the American Journal of Medical Genetics Part A.
“This remarkable case represents the first human example of a disorder that was described by researchers in a transgenic mouse model more than 20 years ago,” said senior author André Bachmann, PhD, Michigan State University professor and associate chair for pediatric research.
“The ODC1 gene plays an important role in a number of physiological and cell developmental processes including embryo and organ development,” said lead author Caleb Bupp, MD, Spectrum Health medical geneticist. “The long-term impacts of this disorder are not completely known.”
Researchers also theorize that the ODC inhibitor DFMO, a water soluble, FDA-approved drug, may serve as a disease-modifying drug, and an early therapeutic trial in a new diagnosis may prevent some of the clinical symptoms. DFMO has been used for many years in the treatment of trypanosomiasis, a tropical disease transmitted by biting insects and more recently entered clinical trials for pediatric neuroblastoma and colon cancer. DFMO prevented hair loss and also partially restored hair growth in mice and is considered a well-tolerated drug.
The female patient was examined at Spectrum Health Helen DeVos Children’s Hospital in Grand Rapids, Michigan, at 11 months of age. Blood samples for testing were drawn at age 19 months and 32 months. Two developmentally normal, age/gender matched patients that were being sedated for outpatient same-day procedures served as controls. The parents of the patients provided written informed consent and the protocol was approved by the institutional review board (IRB) of Spectrum Health.
Bachmann and Bupp were joined in the study by MSU research assistants Chad Schultz and Katie Uhl and Helen DeVos Children’s Hospital Medical Director of Research and critical care physician Surender Rajasekaran, MD.
The original ODC1 mouse model was developed by the late Dr. Thomas G. O’Brien in 1995 at the Lankenau Medical Research Center in Pennsylvania.
Michigan State University has been working to advance the common good in uncommon ways for 160 years. One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world’s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.
Spectrum Health System, a not-for-profit, integrated health system, is committed to improving the health and wellness of our communities. We live our mission every day with 31,000 compassionate professionals, 4,600 medical staff experts, 3,300 committed volunteers and a health plan serving 1 million members. Our talented physicians and caregivers are privileged to offer a full continuum of care and wellness services to our communities through 14 hospitals, including Helen DeVos Children’s Hospital, 150 ambulatory sites and telehealth offerings. We pursue health care solutions for today and tomorrow that diversify our offerings. Locally-governed and based in Grand Rapids, Michigan, our health system provided $550 million in community benefit in calendar year 2019. Thanks to the generosity of our communities, we received $37 million in philanthropy to support research, academics, innovation and clinical care. Spectrum Health has been recognized as one of the nation’s 15 Top Health Systems by Truven Health Analytics®, part of IBM Watson HealthTM.